Institut National de la Santé et de la Recherche Médicale U413, European Institute for Peptide Research (Institut Fédératif de Recherches Multidisciplinaires sur les Peptides 23), Mont-Saint-Aignan, France.
Pharmacol Rev. 2009 Sep;61(3):283-357. doi: 10.1124/pr.109.001370.
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 38-amino acid C-terminally alpha-amidated peptide that was first isolated 20 years ago from an ovine hypothalamic extract on the basis of its ability to stimulate cAMP formation in anterior pituitary cells (Miyata et al., 1989. PACAP belongs to the vasoactive intestinal polypeptide (VIP)-secretin-growth hormone-releasing hormone-glucagon superfamily. The sequence of PACAP has been remarkably well conserved during evolution from protochordates to mammals, suggesting that PACAP is involved in the regulation of important biological functions. PACAP is widely distributed in the brain and peripheral organs, notably in the endocrine pancreas, gonads, respiratory and urogenital tracts. Characterization of the PACAP precursor has revealed the existence of a PACAP-related peptide, the activity of which remains unknown. Two types of PACAP binding sites have been characterized: type I binding sites exhibit a high affinity for PACAP and a much lower affinity for VIP, whereas type II binding sites have similar affinity for PACAP and VIP. Molecular cloning of PACAP receptors has shown the existence of three distinct receptor subtypes: the PACAP-specific PAC1-R, which is coupled to several transduction systems, and the PACAP/VIP-indifferent VPAC1-R and VPAC2-R, which are primarily coupled to adenylyl cyclase. PAC1-Rs are particularly abundant in the brain, the pituitary and the adrenal gland, whereas VPAC receptors are expressed mainly in lung, liver, and testis. The development of transgenic animal models and specific PACAP receptor ligands has strongly contributed to deciphering the various actions of PACAP. Consistent with the wide distribution of PACAP and its receptors, the peptide has now been shown to exert a large array of pharmacological effects and biological functions. The present report reviews the current knowledge concerning the pleiotropic actions of PACAP and discusses its possible use for future therapeutic applications.
垂体腺苷酸环化酶激活肽(PACAP)是一种 38 个氨基酸的 C 末端α-酰胺化肽,它最初是在 20 年前从绵羊下丘脑提取物中分离出来的,其依据是它能够刺激前垂体细胞中环腺苷酸(cAMP)的形成(Miyata 等人,1989 年)。PACAP 属于血管活性肠肽(VIP)-分泌素-生长激素释放激素-胰高血糖素超家族。从原肠动物到哺乳动物,PACAP 的序列在进化过程中得到了很好的保守,这表明 PACAP 参与了重要生物学功能的调节。PACAP 广泛分布于大脑和外周器官,特别是在内分泌胰腺、性腺、呼吸和泌尿生殖道。PACAP 前体的特征揭示了一种 PACAP 相关肽的存在,其活性尚不清楚。已经描述了两种类型的 PACAP 结合位点:I 型结合位点对 PACAP 具有高亲和力,对 VIP 具有低亲和力,而 II 型结合位点对 PACAP 和 VIP 具有相似的亲和力。PACAP 受体的分子克隆表明存在三种不同的受体亚型:PACAP 特异性 PAC1-R,它与几种转导系统偶联,以及 PACAP/VIP 无差别的 VPAC1-R 和 VPAC2-R,它们主要与腺苷酸环化酶偶联。PAC1-R 主要在大脑、垂体和肾上腺中丰富表达,而 VPAC 受体主要在肺、肝和睾丸中表达。转基因动物模型和特异性 PACAP 受体配体的发展为阐明 PACAP 的各种作用做出了重要贡献。与 PACAP 和其受体的广泛分布相一致,该肽现已显示出发挥广泛的药理学作用和生物学功能。本报告综述了关于 PACAP 多效性作用的最新知识,并讨论了其在未来治疗应用中的可能用途。